Original Article

Video-assisted thoracoscopic surgery lobectomy in lung cancer after neoadjuvant chemotherapy: feasibility and security analysis through video-assisted thoracoscopic surgery national registry data evaluation

Gino Zaccagna¹, Carlo Zaraca¹, Gabriella Di Leonardo¹, Luca Bertolaccini², Francesco Zaraca³, Andrea De Vico¹, Carlo Curcio¹, Roberto Crisci¹, Duilio Divisi¹; Italian VATS Group *

¹Thoracic Surgery Unit, University of L'Aquila, “G. Mazzini” Hospital of Teramo, Teramo, Italy; ²Thoracic Surgery Unit, IEO, Milan, Italy; ³Vascular and Thoracic Surgery, Bolzano, Italy; ⁴Thoracic Surgery Unit, “Monaldi” Hospital of Napoli, Napoli, Italy

Contributions: (I) Conception and design: D Divisi, R Crisci; (II) Administrative support: None; (III) Provision of study materials or patients: Italian VATS Group; (IV) Collection and assembly of data: D Divisi, G Zaccagna; (V) Data analysis and interpretation: D Divisi, G Di Leonardo, L Bertolaccini; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Duilio Divisi, MD, PhD. Piazza Italia 1, 64100, Teramo, Italy. Email: duilio.divisi@aslteramo.it.

Background: Lung cancer is the third most diagnosed tumor in Italy and is the leading cause of cancer death in males and the third in females. Video-assisted thoracoscopic surgery lobectomy (VATS-L) represents the gold standard for the treatment of early-stage non-small cell lung cancer (NSCLC). The aim of the study is to evaluate the short-and long-term outcomes of NSCLC patients with stage IIIA N2, treated with neoadjuvant chemotherapy (CHT) followed by VATS lobectomy.

Methods: A retrospective analysis was performed on patients with NSCLC, who underwent VATS-L with (Group A) or without (Group B) neoadjuvant or induction CHT. Out of 6,846 patients enrolled in the VATS Group National Registry, we selected 386 patients with stage IIIA NSCLC (pT1–2, N2). Forty-two patients (10.9%) underwent neoadjuvant or induction CHT and then VATS-L (Group A). The remaining 344 patients (89.1%) underwent VATS-L only (Group B).

Results: The outcomes evaluation between Group A and Group B showed respectively: (I) average length of stay, 9.4 vs. 8.5 days; (II) average duration of pleural drainage, 4.7 vs. 4.6 days; (III) incidence of pneumonia, 4.8% vs. 4.1%; (IV) mortality at 30 days, 0% vs. 0.3%; (V) general mortality, 9.5% vs. 7.3%; (VI) postoperative bleeding necessitating re-intervention and blood transfusion, 4.8% vs. 0.3% and 0% vs. 2.9%; (VII) atrial fibrillation, 16.7% vs. 7.5%; (VIII) prolonged air leaks, 11.9% vs. 7%; (IX) respiratory failure, 0% vs. 0.3%.

Conclusions: Our study confirms that VATS-L in patients with stage IIIA N2 NSCLC treated with neoadjuvant or induction CHT is feasible, oncologically effective and sufficiently safe.

* Italian VATS Group Collaborator List:
Keywords: Advanced non-small cell lung cancer (NSCLC); video-assisted thorascoscopic surgery lobectomy (VATS-L); neoadjuvant chemotherapy (CHT); surgical treatment

Received: 04 December 2019; Accepted: 12 December 2019; Published: 25 May 2020.

do: 10.21037/ccts.2020.01.01

View this article at: http://dx.doi.org/10.21037/ccts.2020.01.01

Introduction

Lung cancer is still considered a “big killer” in Italy, according to the data from the Cancer Registry, it is the third most diagnosed male and female tumor, and is the leading cause of cancer death in sex male and the third in the female. The best treatment options are related to early diagnosis and surgical treatment. Radical surgery for curative purposes consists of resection associated with systematic lymph node dissection (LND). The traditional standard approach by thoracotomy have been replaced by Video-Assisted Thoracoscopic Surgery Lobectomy (VATS-L) in the last twenty years, starting from early stages of lung cancer but currently also used in advanced cancers. Aim of the study was the feasibility and safety evaluation of VATS-L after neoadjuvant or induction chemotherapy (CHT) in patients with non-small cell lung cancer (NSCLC) at stage IIIA.

Methods

The data analyzed in this study were taken from the Italian VATS-Group Registry between January 2014 and December 2018. Criteria in order to be included in the database were as follows: (I) surgery performed exclusively by vision from the monitor; (II) main incision (utility incision) <6 cm in diameter without costal gap; (III) 1 or 2 additional incisions (maximum 1 cm in diameter) can be made; (IV) single dissection of the hilar structures, associated with lymphadenectomy; (V) use of a dedicated bag (endobag) for sample extraction. The extent of lymphadenectomy is defined by the guidelines of the European Society of Thoracic Surgeons (ESTS) (1). A retrospective analysis was performed on IIIA NSCLC patients characterized by: (I) pT1a, b, c or pT2a, b (diameter of the primary lung tumor <5 cm); (II) pN2 (metastasis of mediastinal lymph nodes) and M0. Patients were classified in two Groups based on: (I) neoadjuvant or induction CHT, followed by minimally invasive lobectomy within 1 year of the first CHT (Group A); (II) VATS-L directly, without neoadjuvant or induction CHT (Group B). Patient data included age, gender, Charlson comorbidity score and Eastern Cooperative Oncology Group (ECOG) comorbidity score (2,3) and VATS lobectomy technique. The preoperative clinical stage was established by computed tomography (CT) scan, positron emission tomography-computed tomography (PET/CT) scanning, video-assisted mediastinoscopy (VAM), endobronchial ultrasound/transbronchial needle aspiration (EBUS/TBNA) or transesophageal endoscopic ultrasound/fine-needle aspiration (EUS/FNA). The lower limit of 75 total cases per structure in the analysis was used to include only the data coming from high-volume centers, excluding the beginner. Lymph node staging has been classified according to the guidelines of the European Society of Thoracic Surgeons (ESTS) (4). Perioperative complications have been defined as any deviation from the standard postoperative course within 30 days after the procedure and recorded according to the Clavien-Dindo classification (5,6). The data of follow-up after discharge from the hospital were collected through direct check of patients or by the doctors who performed the last clinical control. In patients with N2 disease, re-staging after induction CHT and before resection was performed routinely. Intraoperative (operative time and conversion rate) and postoperative results (morbidity and mortality within 30 days, duration of chest drainage and length of stay) were analyzed. The extent of the lymphadenectomy was also evaluated. The study was approved by the Italian VATS Group Scientific Committee and by the Ethics Committee of different hospitals.

Statistical analysis

Continuous variables were reported as mean ± standard deviation, while categorical variables were indicated as percentages. Student's test was used to compare continuous data. Pearson's tests and Fisher's exact test were used for categorical variables. Univariate analysis was performed on selected variables. The resulting significant variables at the 0.30 level were included in a Cox multivariate logistic
regression model. Statistical significance was set at 0.05. Statistical analysis was performed using SPSS 24.0 (SPSS Inc., Chicago, IL, USA) and R 3.3.1 (R Core Team, 2016).

**Results**

Of 6,846 patients enrolled in the VATS Group National Registry at the time of extrapolation of the data, we selected 386 NSCLC patients with postoperative IIIA histological staging (pT1–2, N2). Only 10.9% of these (42 cases) underwent neoadjuvant or induction CHT and then VATS-L (Group A) while the remaining 344 (89.1%) patients underwent VATS-L without CHT (control B Group) (Table 1). The indication for neoadjuvant treatment in Group A was the metastasis to N2 lymph nodes (ipsilateral mediastinal and tracheal carina) diagnosed by: (I) conventional transbronchial needle aspiration (TBNA) in 57.2% (n=24) of patients; (II) endobronchial ultrasound/transbronchial needle aspiration (EBUS) in 35.7% (n=15) of patients; (III) mediastinoscopy in 7.1% (n=3) of patients. Regarding the pathological N2 staging, the comparison between Group A and Group B highlighted: (I) positive station 2 (upper paratracheal) lymph nodes in 9 of 42 patients (21.4%) vs. 26 of 344 patients (7.6%, P=0.003); (II) positive station 3 (pre-vascular and retrotracheal) lymph nodes in 0 of 42 patients vs. 4 of 344 patients (1.2%, P=0.50); (III) positive station 4 (lower paratracheal) lymph nodes in 23 of 42 patients (54.8%) vs. 115 of 344 patients (33.4%, P=0.006); (IV) positive station 5 (subaortic) lymph nodes in 1 patient of 42 (2.4%) vs. 82 of 344 patients (23.8%, P=0.001); (V) positive station 6 (para-aortic) lymph nodes in 2 of 42 patients (4.8%) vs. 29 of 344 patients (8.4%, P=0.40); (VI) positive station 7 (subcarinal) lymph nodes in 23 of 42 patients (54.8%) vs. 146 of 344 patients (42.4%, P=0.12); (VII) positive station 8 (paraesophageal) lymph nodes in 3 of 42 patients (7.1%) vs. 30 of 344 patients (8.7%, P=0.72); (VIII) positive station 9 (pulmonary ligament) lymph nodes in 1 of 42 patients (2.4%) vs. 20 of 344 patients (5.8%, P=0.35). The incidence of metastases at multiple lymph node stations was statistically higher in Group A (20 of 42 patients, 47.6%) than Group B (108 of 344 patients, 31.4%) (P=0.03). About the histology, 31 Group A patients (73.8%) displayed an adenocarcinoma vs. 281 Group B patients (81.7%) (P=0.22) while squamous cell carcinoma histotype was found mostly in Group A (10 patients, 23.8%) compared to Group B (37 patients, 10.8%; P=0.014). Other subtypes such as large cell carcinoma, carcinoid tumors and pleomorphic carcinoma were found only in Group B at the rate of 0.6% (2 patients, P=0.20), 3.2% (11 patients, P=0.77) and 0.6% (2 patients, P=0.20) respectively. Short-term perioperative outcomes were monitored in both Groups and the collected data were the following: (I) average length

---

**Table 1 Patient characteristics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group A (n=42)</th>
<th>Group B (n=344)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, female n. (%)</td>
<td>18 (42.9)</td>
<td>137 (39.8)</td>
<td>0.70</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>67.4±8.3</td>
<td>66.7±10.3</td>
<td>0.69</td>
</tr>
<tr>
<td>FEV1 (mean ± SD) (% of predict)</td>
<td>95.7±23.7</td>
<td>93.8±19.6</td>
<td>0.60</td>
</tr>
<tr>
<td>DLCO (mean ± SD) (% of predict)</td>
<td>80.3±22.1</td>
<td>81.4±24.1</td>
<td>0.79</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>10 (23.8)</td>
<td>48 (14.0)</td>
<td>0.09</td>
</tr>
<tr>
<td>Renal disease (n, %)</td>
<td>0 (0.0)</td>
<td>15 (4.4)</td>
<td>0.54</td>
</tr>
<tr>
<td>COPD (n, %)</td>
<td>9 (21.4)</td>
<td>83 (24.1)</td>
<td>0.69</td>
</tr>
<tr>
<td>Vascular disease (n, %)</td>
<td>9 (21.4)</td>
<td>49 (14.2)</td>
<td>0.047</td>
</tr>
<tr>
<td>Congestive heart failure (n, %)</td>
<td>1 (2.4)</td>
<td>9 (2.6)</td>
<td>0.92</td>
</tr>
<tr>
<td>Cerebrovascular diseases (n, %)</td>
<td>3 (7.1)</td>
<td>15 (4.4)</td>
<td>0.41</td>
</tr>
<tr>
<td>Coronaric disease (n, %)</td>
<td>1 (2.4)</td>
<td>36 (10.5)</td>
<td>0.09</td>
</tr>
<tr>
<td>History of cigarettes smoking (n, %)</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
</tr>
<tr>
<td>Previous extrathoracic malign neoplasia (n, %)</td>
<td>0 (0.0)</td>
<td>7 (2.0)</td>
<td>0.88</td>
</tr>
</tbody>
</table>

FEV1, forced expiratory volume in 1 second; DLCO, diffusion lung carbon monoxide; COPD, chronic obstructive pulmonary disease.
of hospital stay, 9.4 days in Group A vs. 8.5 days in group B (P=0.32); (II) average length of chest drainage, 4.7 days in Group A vs. 4.6 days in group B (P=0.91); (III) rate of pneumonia, 4.8% in Group A (2 of 42 patients) vs. 4.1% in Group B (14 of 344 patients; P=0.83); (IV) 30-day mortality, 0% in Group A vs. 0.3% in Group B (1 of 344 patients) (P=0.75); (V) overall mortality, 9.5% in Group A (4 of 42 patients) vs. 7.3% in Group B (25 of 344 patients) (P=0.60); (VI) postoperative bleeding requiring reoperation, 4.8% in Group A (2 of 42 patients) vs. 0.3% in Group B (1 of 344 patients) (P=0.001); (VII) postoperative bleeding requiring blood transfusion, 0% in Group A vs. 2.9% in Group B (10 of 344 patients) (P=0.84); (VIII) atrial fibrillation, 16.7% in Group A (7 of 42 patients) vs. 7.5% in Group B (26 of 344 patients) (P=0.04); (IX) prolonged air leaks, 11.9% in Group A (5 of 42 patients) vs. 7.0% in Group B (24 of 344 patients) (P=0.25); (X) respiratory failure, 0% in Group A vs. 0.3% in Group B (1 of 344 patients) (P=0.75); (XI) other complications (myocardial ischemia, ictus, pulmonary embolism) 0% in Group A vs. 6.7% in Group B, (23 of 344 patients) (P=0.27). Conversion from VATS-L to open thoracotomy were 14.3% in Group A (6 of 42 patients) vs. 11.3% in Group B (39 of 344 patients) (P=0.57); no conversion was due to difficulty in performing dissection linked to fibrous tissue in patients undergoing neoadjuvant treatment. The reasons for conversion in Group A (6 patients) and in Group B (39 patients) were respectively: (I) pleuroparenchymal adhesions, 3 patients (50%) vs. 11 patients (28.2%); (II) bleeding, 1 patient (16.7%) vs. 11 patients (28.2%); (III) difficulty in pulmonary artery dissection due to calcific perivascular lymph nodes, 1 patient (16.7%) vs. 13 patients (33.3%); (IV) anomaly in anatomy, 1 patient (16.7%) vs. 4 patient (10.3%).

Survival analysis

In regard to the analysis of survival, we have extrapolated the data relating to the follow-up of Group A in the 5-year timeframe from 2014 to 2019. The relapses showed a maximum probability level in the first follow-up period (about 180 days) and then decrease over time until reaching a stability after one year (Figure 1). Survival according to the Kaplan-Meier test decreased over time, with a high rate in the first year and remaining still higher than 0.5 even at the end of the follow-up (Figure 2).

Discussion

In recent years we observed a continuous expansion of VATS-L indications. Neoadjuvant CHT followed by a VATS-L in patients at stage IIIA N2 NSCLC represents one of the most interesting research frontiers not yet fully explored in the literature (7-11). Mollberg et al. (12) analyzed 65 patients with NSCLC larger than 2 cm in stage III, N2. After neoadjuvant CHT, patients were re-staged with PET/CT and underwent VATS-L only if no signs of disease progression were found. Although the Authors defined some contraindications to VATS-L, such as the infiltration of the chest wall by the tumor or the presence of calcifications near the pulmonary artery, the study did not draw conclusions on the safety and efficacy of VATS-L after neoadjuvant CHT due to the low number of patients examined. Huang et al. (13) retrospectively studied 42 patients undergoing induction therapy (CHT in 27 patients}
and CHT + RT followed by VATS resection in 16 patients) diagnosed at stage IIIA in most of them (63%). Thirty-three patients (77%) underwent lobectomy or bilobectomy, 4 patients (9%) pneumonectomy and 5 patients (12%) wedge resection. The total complication and mortality rate were 12% and 2% respectively but these parameters were not stratified according to the extent of resection or the type of induction therapy. Petersen et al. (14) examined outcomes in 97 patients undergone induction therapy followed by pulmonary resection, comparing VATS-L (8 patients received induction CHT + RT while 4 patients received CHT alone) versus open lobectomy (85 patients). Both Groups were homogeneous about demographic characteristics, lung function, comorbidities, factor T and N. No significant difference between the two groups was found as regards the number of lymph nodes removed, the 30-day mortality rate, major complications, overall survival and 2 years recurrences. However, VATS-L patients displayed a statistically shorter average length of hospital stay (3.5 vs. 5 days) and of chest drainage (2 vs. 4 days). Yang et al. (15) studied 272 patients undergoing induction therapy followed by VATS (69 patients) or thoracotomy (203 patients) lobectomy. Authors found no statistically significant difference in the thirty-day mortality between the two groups: VATS 3% vs. open 4% (P=0.69). The 3-year survival of VATS was better than that of thoracotomy (61% vs. 43%, P=0.010), with a tendency towards survival improvement only in VATS patients (hazard ratio, 0.56; 95% confidence interval, 0.32–1.01; P=0.053). Authors concluded that neoadjuvant CHT should not be considered a contraindication to VATS-L in patients with advanced NSCLC. In our experience, the comparison between Group A and Group B showed a greater number T2b N2 patients with frequent involvement of 2 and 4 ipsilateral lymph node station. In contrast, Group B highlighted a greater infiltration of the 5 lymph node stations. This statistically significant difference (P=0.001) can be ascribed to a better and easier preoperative evaluation of stations 2 and 4 compared to station 5 by endobronchial – esophageal ultrasound or VAM, with reduced risk of lung cancer upstaging or downstaging and focused treatment strategy. Group A compared to Group B also displayed a higher postoperative percentage of bleeding and atrial fibrillation, with statistical significance. Evidently, VATS-L after neoadjuvant CHT was burdened by an alteration of platelet activity (16-19) and of electrical stimulation of the heart probably due to risk factors and systemic inflammation (20-23). The coagulation mechanisms depend on a balance between thrombotic and anti-thrombotic factors. In cancer patients, the reduced levels of coagulation inhibitors, antiphospholipid antibodies and tumor-derived tissue factor (TF) determine an alteration of fibrinolysis and activated protein C linked to the hypercoagulation. Obviously, postoperative disseminated intravascular coagulation may more easily occur with platelet consumption and bleeding. Coagulation disorders are also accentuated by diabetes, which we found in many patients in the two Groups. These clinical situations require reoperation and new coagulation set-up as blood transfusions may not be enough (17-19). Several studies in literature displayed a correlation between CHT and atrial fibrillation (FA). Xie et al. (20) analyzed 144 patients carried out thoracotomy. Eighteen patients showed postoperative FA, 7 of which (38.9%) undergone neoadjuvant CHT. One hundred twenty-six patients did not develop FA, 19 of which (15.1%) undergone neoadjuvant CHT. Guglin et al. (21) examined the published papers on arrhythmias due to CHT, using the PubMed/Medline and OVID databases from 1,950 onwards to better understand this correlation. Particularly, cisplatin and melfalan are associated with FA rates ranging from 12% to 32% and from 7% to 12% respectively. However, the development of atrial fibrillation could depend on a structural and electrical myocardial remodeling and not just from CHT (22). Also, we revealed more chronic obstructive pulmonary disease (COPD) patients in Group A than Group B. Correlation between COPD and atrial fibrillation has already wide studied in literature (23,24). Konecny et al. (25), analyzing data from 741 patients who undergone pulmonary function tests and 24-hour Holter, showed 3121 COPD patients (41%). These patients, compared to those without COPD, developed FA (23.3% vs. 11.0%, P<0.0001) and ventricular tachycardia (13.0% vs. 5.9% respectively, P<0.0001) more easily.

Conclusions

In conclusion, our study confirmed that VATS-L in stage IIIA N2 non-small cell lung cancer patients treated with neoadjuvant CHT is feasible, oncologically effective and sufficiently safe. However, should be considered the high postoperative risk of major bleeding and atrial fibrillation, requiring compliance with the international guidelines for high-risk patients in order to prevent these complications.

Acknowledgments

None.
Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

23. Goudis CA. Chronic obstructive pulmonary disease and


doi: 10.21037/ccts.2020.01.01